18F-FET-PET guided surgical biopsy and resection in children and adolescence with brain tumors

Misch, Martin; Guggemos, Andreas; Driever, Pablo Hernáiz; Koch, Arend; Grosse, F.; Steffen, Ingo G.; Plotkin, Michail; Thomale, Ulrich‐Wilhelm

doi:10.1007/s00381-014-2552-y

Cited by 48 publications

(31 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Since the 18 F-labeled amino acid tracer FET (half-life, 110 minutes) overcomes the logistic disadvantages of MET, FET PET has been intensively evaluated over the last two decades for the detection of vital tumour tissue for biopsy guidance and treatment planning, especially neurosurgical resection or radiotherapy [37]. Usually, summed…”

Section: Discussionmentioning

confidence: 99%

FET PET reveals considerable spatial differences in tumour burden compared to conventional MRI in newly diagnosed glioblastoma

Lohmann

Stavrinou

Lipke

et al. 2018

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

Purpose: Contrast enhancement (CE) in MRI is usually the target for resection or radiotherapy target volume definition in glioblastomas. However, the solid tumour mass may extend beyond areas of CE. Amino acid PET can detect such tumour parts that show no CE. We systematically investigated tumour volumes delineated by amino acid PET and MRI in newly diagnosed, untreated glioblastoma patients. Methods: Preoperatively, 50 patients with neuropathologically confirmed glioblastoma underwent O-(2-[ 18 F]-fluoroethyl)-L-tyrosine (FET) PET, fluid-attenuated inversion recovery (FLAIR) and contrast-enhanced MRI. Areas of CE were manually segmented. FET PET tumour volumes were segmented using a tumour-to-brain ratio ≥1.6. The percentage of overlapping volumes (OV), Dice and Jaccard spatial similarity coefficients (DSC; JSC) were calculated. FLAIR images were evaluated visually. Results: In 86% of patients (n=43), the FET tumour volume was significantly larger than the volume of CE (21.5±14.3 mL vs. 9.4±11.3 mL; P<0.001). Forty patients (80%) showed both an increased uptake of FET and CE. In these 40 patients, the spatial similarity between FET and CE was low (mean DSC, 0.39±0.21; mean JSC, 0.26±0.16). Ten patients (20%) showed no CE, and one of these patients showed no FET uptake. In 10% of patients (n=5), increased FET uptake was present outside of areas of FLAIR hyperintensity. Conclusions: Our data show that the metabolically active tumour volume delineated by FET PET is significantly larger than tumour volume delineated by CE. Furthermore, the data strongly suggest that the information derived from both imaging modalities should be integrated into the management of newly diagnosed glioblastoma patients.

show abstract

Section: Discussionmentioning

confidence: 99%

FET PET reveals considerable spatial differences in tumour burden compared to conventional MRI in newly diagnosed glioblastoma

Lohmann

Stavrinou

Lipke

et al. 2018

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

show abstract

“…Amino acid 18 F-fluoroethyl-tyrosine PET (FET PET) has been used to identify metabolically active tumor tissue and to differentiate it from therapy-associated changes. A study by Misch et al [17] showed that the indications for FET PET were visualization of metabolically active malignant tissue within anatomically defined lesions or previously treated tumors and assessment of their extent (Fig. 1).…”

Section: Brainmentioning

confidence: 99%

PET Molecular Imaging–Directed Biopsy: A Review

Fei

Schuster

2017

American Journal of Roentgenology

View full text Add to dashboard Cite

show abstract

“…This enables the visualization of anaplastic regions even in areas that are not enhanced by contrast agents on MRI and where the BBB is assumed to be intact [7,40]. Amino acid PET imaging has shown to be promising for diagnostic purposes, as well as for biopsy and resection surgery planning [41][42][43]. Amino acid tracers also perform particularly well in differentiating early tumor progression from pseudoprogression (i.e., imaging changes that mimic a progressive tumor, but that are actually due to other causes, most commonly inflammation related to therapy), with significant higher SUVs or TBRs in (recurrent) LGG and HGG, and brain metastases compared to lesions with pseudoprogression [44][45][46].…”

Section: Diagnostic Imaging Of Abnormal Metabolic Processesmentioning

confidence: 99%

The Added Value of Diagnostic and Theranostic PET Imaging for the Treatment of CNS Tumors

Pruis

Dongen

Zanten

2020

IJMS

View full text Add to dashboard Cite

This review highlights the added value of PET imaging in Central Nervous System (CNS) tumors, which is a tool that has rapidly evolved from a merely diagnostic setting to multimodal molecular diagnostics and the guidance of targeted therapy. PET is the method of choice for studying target expression and target binding behind the assumedly intact blood–brain barrier. Today, a variety of diagnostic PET tracers can be used for the primary staging of CNS tumors and to determine the effect of therapy. Additionally, theranostic PET tracers are increasingly used in the context of pharmaceutical and radiopharmaceutical drug development and application. In this approach, a single targeted drug is used for PET diagnosis, upon the coupling of a PET radionuclide, as well as for targeted (nuclide) therapy. Theranostic PET tracers have the potential to serve as a non-invasive whole body navigator in the selection of the most effective drug candidates and their most optimal dose and administration route, together with the potential to serve as a predictive biomarker in the selection of patients who are most likely to benefit from treatment. PET imaging supports the transition from trial and error medicine to predictive, preventive, and personalized medicine, hopefully leading to improved quality of life for patients and more cost-effective care.

show abstract

18F-FET-PET guided surgical biopsy and resection in children and adolescence with brain tumors

Cited by 48 publications

References 21 publications

FET PET reveals considerable spatial differences in tumour burden compared to conventional MRI in newly diagnosed glioblastoma

FET PET reveals considerable spatial differences in tumour burden compared to conventional MRI in newly diagnosed glioblastoma

PET Molecular Imaging–Directed Biopsy: A Review

The Added Value of Diagnostic and Theranostic PET Imaging for the Treatment of CNS Tumors

Contact Info

Product

Resources

About